---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-148076"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T07:53:12.932447+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Inovio grants performance-based RSUs tied to INO-3107 milestones; stockholders re-elect board

## Summary
- CEO Shea receives 33,200 target PSUs; CFO Kies and CSO Humeau each receive 8,900 target PSUs.
- Up to 70% of PSUs vest on INO-3107 milestones (FDA approval, launch, market share, sales) by 2025-2027.
- Remaining 30% vest on relative TSR vs. Russell 2000 Biotech index June 2024-Dec 2027 (50%-150% of target).
- Stockholders ratified Ernst & Young as auditor (11.1M for) and approved non-binding say-on-pay (3.0M for).
- All eight director nominees elected with votes ranging 3.1M-3.8M for.

## SEC filing metadata
- accession: 0001193125-24-148076
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312524148076/0001193125-24-148076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312524148076/d597714d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-148076
- JSON: https://secwatch.observer/filing/0001193125-24-148076.json
- Plain text: https://secwatch.observer/filing/0001193125-24-148076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.